ACAD is not sitting where it is right now based on earnings. they really have no earnings, they are where they are based on what could very well be a blockbuster drug for psycosis in parkinsons disease. all small biotechs are struggling right now! ACAD will have its day in the sun soon. I have bought the bulk of my position under 3.00 per share but i am buying even today at what i think will be a bargain down the road. just my opinion, do your own due diligence.